ClinicalTrials.gg
CompletedNCT05216497Updated Jul 27, 2023

Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

A Phase 3 interventional study of Ingavirin®, 90 mg capsules and Placebo in COVID-19, sponsored by Valenta Pharm JSC. Completed at 14 sites in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2021, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in COVID-19 with a site in Russian Federation — 4 open to participants now, 9 under way, 1 of them phase 3. COVID-19 · Russian Federation.

Enrollment
46th of 105
233 · median 198
Started
2021
with 37 others
Phase 3
40 of 144
none open now
Registered
114th of 144
by date

Among the 144 studies in COVID-19 with a site in Russian Federation, this one is the 46th largest by enrollment of the 105 interventional ones that give a count, is one of 38 that started in 2021, is one of 40 in phase 3, and was the 114th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 144 studies in COVID-19 with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in COVID-19 with a site in Russian Federation, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms. A secondary goal of this study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19 infection.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written of the patient to participate in the study.
  2. Patients aged 18-75 years inclusive.
  3. COVID-19 diagnosis based on laboratory confirmation of SARS-CoV-2 virus, conducted within 3 days prior to the first dose of the drug. Determination of SARS-CoV-2 virus by polymerase chain reaction (PCR) or other method regulated by the actual clinical recommendations is acceptable.
  4. Patients with a mild course of COVID-19 - presence of at least 2 criteria: SpO2 ≥ 95% (mandatory criterion), body temperature ˂ 38°C, respiratory rate (RR) ≤ 22/min.
  5. Duration of illness not more than 3 full days from the onset of one or more of the following symptoms until the first dose of study drug: elevated body temperature; dry cough or cough with small amount of sputum; shortness of breath; myalgia; fatigue; feeling of stuffiness in the chest; sore throat; nasal congestion/rhinorrhea; headache; feeling of heat or fever; decreased sense of smell and/or taste.
  6. Presence of at least two symptoms on the COVID-19 Core Symptom Rating Scale with a score of 2 or more.
  7. Women only: Negative pregnancy test result. The pregnancy test need not be performed on women who are not fertile: women who are menopausal (defined as not menstruating for at least two years or more) or who have had surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) or have a clinical diagnosis of infertility. The presence of surgical sterilization and infertility is evaluated on the patient's word or with a document confirming this condition.
  8. Women with preserved and men whose partners have preserved reproductive potential agree to abstain from sexual intercourse for the duration of the study.
  9. Patients who are able to understand and comply with the treatment and procedures of the study.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to the active ingredient or any of the of the study drug.
  2. Known or suspected hypersensitivity to standard therapies.
  3. Presence of criteria for moderate to severe disease.
  4. Need for hospitalization at the time of screening or randomization.
  5. Body temperature ˂ 37.5°C.
  6. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
  7. Presence of cancer within the past 2 years, or current suspicion of cancer.
  8. History or current disease.
  9. Pregnancy.
  10. Breastfeeding period.
  11. Presence of serious lung diseases (the list can be expanded at the discretion of the investigator): moderate-to-severe bronchial asthma, severe to very severe (COPD), interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, lung surgeries, tuberculosis (including suspected tuberculosis based on CT scan of the lungs at screening).
  12. Patients with the presence of type 1 diabetes mellitus and/or decompensated type 2 diabetes mellitus.
  13. Heart failure, (NYHA) functional class III-IV.
  14. Chronic liver failure stage II (decompensated) and higher.
  15. Need for renal replacement therapy at the time of inclusion
  16. History of organ transplantation.
  17. History of epilepsy or need for anticonvulsant therapy.
  18. Major depressive disorder, anxiety, other mental disorders requiring medication correction.
  19. Acute cerebral circulation disorder, stroke, or within 90 days prior to screening.
  20. Taking any antiviral and/or immunomodulatory drugs after COVID-19 manifestation.
  21. Use of any therapy (including tocilizumab/sarilumab) within 90 days prior to randomization, or need for immunosuppressive therapy at the time of randomization.
  22. Use of anticoagulation plasma for 14 days prior to screening.
  23. Use of systemic glucocorticosteroids within 90 days prior to the time of randomization, or the need to prescribe systemic glucocorticosteroids at the time of randomization.
  24. History of COVID-19 vaccination.
  25. Use of vaccines against viral infections within 90 days prior to the time of randomization.
  26. Patients taking or having taken other experimental drugs, drugs not approved in the Russian Federation, or participating or having participated in other clinical trials within 30 days prior to screening.
  27. Abuse of alcohol or psychotropic drugs and other medications currently or within the last year.
  28. Patients with other serious, unstable or medical or psychological conditions that, in the opinion of the investigator, may interfere with the patient's participation in the study.

Withdrawal Criteria:

  1. Withdrawal of consent;
  2. AEs that make it impossible to participate in the study or require emergency medical care in an inpatient setting (except in cases of hospitalization related to the patient's transition to a moderate to severe course of COVID-19);
  3. Serious protocol violations and refusal of the participant(s) to comply with study protocol or procedures (e.g., use of protocol-prohibited therapy);
  4. Pregnancy;
  5. Necessity for use of medications forbidden by the protocol.
  6. Participant is lost to follow-up;
  7. Death of the participant;
  8. Decision of the Sponsor or Investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Ingavirin®, 90 mg capsules

    Ingavirin®, 90 mg capsules will be administered on top of standard therapy: days 1-3: 180 mg (2 capsules once a day); days 4-7: 90 mg (1 capsule 1 time per day).

    Drug: Ingavirin®, 90 mg capsules

  • Placebo comparator
    Placebo

    Placebo capsules will be administered on top of standard therapy: days 1-3: 2 capsules once a day; days 4-7: 1 capsule 1 time per day.

    Drug: Placebo

Interventions

  • 90-180 mg/day for 7 days on top of standard therapy

  • DrugPlacebo

    1-2 capsules for 7 days on top of standard therapy

06

What researchers measure

Primary outcomes

  1. Time to clinical recovery

    Time (in hours from first dose) to clinical recovery as assessed by Hazard Ratio analysis. Clinical recovery refers to a score of ≤1 on the COVID-19 Core Symptom Rating Scale for each symptom.

    Time frame: Day 2-28

Secondary outcomes

  1. Assessment of patient status

    Proportion of patients with improvement of one category or more on the World Health Organization (WHO) scale by Days 2-28; proportion of patients with deterioration by one category or more on Days 2-28; average change in WHO category by Day 2-28 from baseline; proportion of patients with progression to WHO category 3 or higher by Day 14.

    Time frame: Day 2-28

  2. Assessment of clinical measures

    Proportion of patients with oxygen saturation (SpO2) ≤ 93%; proportion of patients with SpO2 ˂ 95%; average change in SpO2 compared to baseline; proportion of patients with respiratory rate (RR) \> 30/min; proportion of patients with RR \> 22/min; proportion of patients with RR ≤ 20/min; average change in RR; proportion of patients with fever ≤ 37.0°C; proportion of patients with fever ≤ 37.5°C; proportion of patients with temperatures ≥38.5°C; mean change in temperature from baseline.

    Time frame: Day 2-28

  3. Symptom Score

    Proportion of patients with a score ≤ 1 on the Daytime and Nighttime Cough Scale; average change in cough scale score from baseline; mean time to reach ≤ 1 score on the cough scale; percentage of patients with a decrease of 1 point or more on each symptom on the COVID-19 symptom scale; percentage of patients with clinical improvement (1 point or less) on each symptom on the COVID-19 symptom scale; percentage of patients with a score ≤ 1 on each symptom on the COVID-19 symptom scale; average change in score for each symptom on the COVID-19 symptom scale from baseline; average time to reach a score ≤ 1 on each symptom on the COVID-19 symptom scale.

    Time frame: Day 2-28

  4. Evaluation of laboratory and instrumental examinations

    Percentage of patients negative for Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) by Day 4, 8, 14, 21, 28 (if positive on previous examination); mean change in SARS-CoV-2 concentration by Day 8; time to SARS-CoV-2 elimination.

    Time frame: Day 2-28

Other outcomes

  1. Status assessment

    Percentage of patients hospitalized during the study; length of hospitalization; proportion of patients transferred to the ICU during hospitalization; length of stay in the ICU; proportion of patients with acute respiratory distress syndrome during hospitalization; presence of fatal outcome.

    Time frame: Day 2-28

  2. Assessment of respiratory support

    Percentage of patients needing oxygen therapy; percentage of patients needing high-flow oxygen therapy; percentage of patients needing noninvasive ventilation; percentage of patients needing invasive ventilation; percentage of patients needing extracorporeal membrane oxygenation (ECMO); total duration of oxygen therapy by the last day of hospitalization; total duration of high-flow oxygen therapy by the last day of hospitalization; total duration of noninvasive ventilation by the last day of hospitalization; total duration of invasive ventilation by the last day of hospitalization; cumulative duration of ECMO by the last day of hospitalization.

    Time frame: Day 2-28

  3. X-Ray evaluation

    Proportion of patients with CT-1 or higher (CT-2, CT-3, and CT-4) according to lung CT data; proportion of patients with CT-0.

    Time frame: Day 2-28

  4. Safety assessment

    Number and incidence of adverse events (AEs) reported during the study after study drug use and characteristics of AEs (intensity, severity, frequency, severity, expectancy, association with study therapy); number and frequency of serious adverse events (SAEs) reported during the study after the use of the study drug, and characteristics of SAEs (intensity, severity, frequency, severity, expectancy, association with the study therapy).

    Time frame: Day 2-28

07

Study locations

14 sites
  • Municipal Budgetary Institution of Healthcare "Central City Hospital of Novoshakhtinsk"
    Novoshakhtinsk, Rostov Region 346918, Russian Federation
  • "4D Ultrasound Clinic" LLC
    Pyatigorsk, Stavropol' Region 357502, Russian Federation
  • "Family Clinic" LLC
    Ekaterinburg, 620102, Russian Federation
  • Ivanovo Kuvaev Clinical Hospital
    Ivanovo, 153025, Russian Federation
  • State Budgetary Institution of Healthcare of Moscow "City Polyclinic No. 2 of the Moscow Department of Healthcare"
    Moscow, 117556, Russian Federation
  • Unimed-C Jsc
    Moscow, 119571, Russian Federation
  • Ryazan State Medical University named after Academician I.P. Pavlova
    Ryazan', 390026, Russian Federation
  • State Budgetary Institution of the Ryazan Region "Regional Clinical Hospital"
    Ryazan', 390039, Russian Federation
  • Limited Liability Company "Medical Center "Capital-Policy"
    Saint Petersburg, 190013, Russian Federation
  • Saint Petersburg State Budgetary Healthcare Institution "City polyclinic No. 112"
    Saint Petersburg, 195427, Russian Federation
  • Limited Liability Company "Research Center Eco-Safety"
    Saint Petersburg, 196143, Russian Federation
  • St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 117"
    Saint Petersburg, 196143, Russian Federation
  • Saint Petersburg State Budgetary Institution of Healthcare "City Pokrovskaya Hospital"
    Saint Petersburg, 199106, Russian Federation
  • Astarta LLC
    Saint Petersburg, 199226, Russian Federation
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jan 2022, 3 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Jan 31, 2022
StartActual
Oct 6, 2021
Primary completionActual
Jan 12, 2022
CompletionActual
Apr 25, 2022
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05216497
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Oct 6, 2021
Primary completion
Jan 12, 2022
Completion
Apr 25, 2022
Last update
Jul 27, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide

Start the discussion